Respiratory

Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.

Asthma is worsening under the effects of climate change, such as air pollution and pollen production, especially for underserved populations.

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.

Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.

An exploration of idiopathic bronchiectasis, emphasizing the importance of patient participation in clinical trials to advance knowledge and treatment options for this condition, along with concluding thoughts and key takeaways on the management and understanding of bronchiectasis.

Our top coverage from the CHEST Annual Meeting 2023 explored various topics, including strategies to prevent air pollutant exposure and keys to achieving equity in lung cancer screenings.

This year’s most-read respiratory articles explored a variety of topics, including the effects of marijuana and vaping on the lungs.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.

A new study shows that a mother's inflammatory diet before birth can have an impact on a child's wheeze trajectory.

The warning letters issued to 7 manufacturers are part of a larger, ongoing effort by the FDA to address the manufacturing, distribution, and sale of illegal and unauthorized e-cigarettes.

This new data suggests that hospital facilities in the US may need to plan for potentially atypical timing of bronchiolitis season once more for 2023.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.

CDC plans to monitor over 30 pathogens in high-risk airports; a surge in ketamine prescriptions raises questions about safety and oversight; changes to come in Affordable Care Act (ACA) enrollment for 2023.

Despite e-cigarette use dropping 4.1% in the past year, it is still the most commonly used tobacco product among both middle and high school students.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

Patients with Medicare were 5.08 times more likely than patients with private insurance, and 2.81 times more likely than patients with Medicaid, to face a financial barrier to obtaining varenicline and combination nicotine replacement therapy.

To reduce the global burden of respiratory diseases and tackle inequalities, the Forum of International Respiratory Studies and the American Thoracic Society suggested improving access to preventive services, inhaler therapies, and effective pneumonia vaccines.

The study’s findings provide support for the use of precessation varenicline and nicotine patches in an adaptive treatment regimen where bupropion is provided to treat nonresponders.

Researchers found that individuals who used e-cigarettes had a higher smoking abstinence rate in late pregnancy than those who used nicotine reduction therapy, especially for those who began using e-cigarettes before pregnancy.